Literature DB >> 8405010

Effect of ipratropium on nasal reactivity to histamine and eosinophil influx in perennial allergic rhinitis.

P Górski1, K Pazdrak, U Ruta.   

Abstract

In a double-blind, placebo-controlled study nasal saline and histamine provocation tests were performed in patients with perennial allergic rhinitis in order to assess changes in eosinophil influx and non-specific nasal reactivity after 8 days of treatment with ipratropium bromide. A "nasal pool" method was used to trace changes in protein level and eosinophil influx into nasal secretions. Treatment with ipratropium 80 mg q.i.d. caused a significant decrease in the albumin and total protein level in saline washings and induced a five-fold increase in eosinophils as compared to the placebo treatment. The nasal mucosal response to histamine, assessed as the number of sneezes and protein level, was more responsive to ipratropium treatment than the mucosa from placebo-treated subjects. Since eosinophil numbers were correlated with an increase in the vascular and sneezing responses, it appears that ipratropium potentiates inflammatory mechanisms when used in subjects with an allergy in the nasal mucosa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405010     DOI: 10.1007/bf02440856

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Adverse reaction to ipratropium bromide.

Authors:  C K Connolly
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-02

2.  Pathophysiology of rhinitis. 1. Assessment of the sources of protein in methacholine-induced nasal secretions.

Authors:  G D Raphael; H M Druce; J N Baraniuk; M A Kaliner
Journal:  Am Rev Respir Dis       Date:  1988-08

3.  A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects.

Authors:  P A Minette; J W Lammers; C M Dixon; M T McCusker; P J Barnes
Journal:  J Appl Physiol (1985)       Date:  1989-12

4.  Ipratropium in the treatment of patients with perennial rhinitis.

Authors:  I Sjögren; J Juhász
Journal:  Allergy       Date:  1984-08       Impact factor: 13.146

5.  The pathophysiology of rhinitis. II. Assessment of the sources of protein in histamine-induced nasal secretions.

Authors:  G D Raphael; S D Meredith; J N Baraniuk; H M Druce; S M Banks; M A Kaliner
Journal:  Am Rev Respir Dis       Date:  1989-03

Review 6.  Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

7.  Ipratropium treatment for rhinorrhoea in patients with perennial rhinitis. An open follow-up study of efficacy and safety.

Authors:  F Schultz Larsen; N Mygind; F S Larsen
Journal:  Clin Otolaryngol Allied Sci       Date:  1983-08

8.  The effect of locally applied ipratropium aerosol on the nasal methacholine challenge in patients with allergic and non-allergic rhinitis.

Authors:  S Sanwikarja; P I Schmitz; P H Dieges
Journal:  Ann Allergy       Date:  1986-02

9.  Control of the hypersecretion of vasomotor rhinitis by topical ipratropium bromide.

Authors:  J Dolovich; L Kennedy; F Vickerson; F Kazim
Journal:  J Allergy Clin Immunol       Date:  1987-09       Impact factor: 10.793

10.  Comparison of human nasal mucosal secretion in vivo and in vitro.

Authors:  J Mullol; G D Raphael; J D Lundgren; J N Baraniuk; M Mérida; J H Shelhamer; M A Kaliner
Journal:  J Allergy Clin Immunol       Date:  1992-02       Impact factor: 10.793

View more
  3 in total

Review 1.  Neural control of airway inflammation.

Authors:  Kirsten C Verhein; Allison D Fryer; David B Jacoby
Journal:  Curr Allergy Asthma Rep       Date:  2009-11       Impact factor: 4.806

2.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

3.  Atropine-enhanced, antigen challenge-induced airway hyperreactivity in guinea pigs is mediated by eosinophils and nerve growth factor.

Authors:  Norah G Verbout; David B Jacoby; Gerald J Gleich; Allison D Fryer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-05-15       Impact factor: 5.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.